Borderline Personality Disorder Clinical Trial
— BrainBoostOfficial title:
BrainBoost - A Neurofeedback Booster for Emotion Regulation Therapy
NCT number | NCT04333888 |
Other study ID # | 2020-513N |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | July 21, 2020 |
Est. completion date | May 2023 |
This is a proof-of-concept study that aims to test the additional value of adjuvant neurofeedback treatment for psychotherapy. Three sessions of real-time fMRI neurofeedback will be administered to N=22 patients with BPD while they receive residential Dialectical Behavior Therapy treatment. In addition, outcomes are assessed from a control group with same sample size who do not receive the treatment.
Status | Recruiting |
Enrollment | 44 |
Est. completion date | May 2023 |
Est. primary completion date | May 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - DSM-5 BPD diagnosis - informed consent - EtOH and tox negative on the day of neurofeedback - BSL-23 score >=1.87 at DBT halftime Exclusion Criteria: - pharmacotherapy with opiates - standing benzodiazepines (bedtime-only benzodiazepines and anti-histamines allowed) - pregnancy - epilepsy - life-time diagnosis schizophrenia or bipolar disorder I - significant current or past neurological illness - BMI<16.5 - usual safety criteria for magnetic resonance imaging |
Country | Name | City | State |
---|---|---|---|
Germany | Central Institute of Mental Health | Mannheim |
Lead Sponsor | Collaborator |
---|---|
Christian Paret | AE Foundation, Yale University |
Germany,
Zaehringer J, Ende G, Santangelo P, Kleindienst N, Ruf M, Bertsch K, Bohus M, Schmahl C, Paret C. Improved emotion regulation after neurofeedback: A single-arm trial in patients with borderline personality disorder. Neuroimage Clin. 2019;24:102032. doi: 10.1016/j.nicl.2019.102032. Epub 2019 Oct 16. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in affective instability | Mean successive squared differences (MSSD) of six-item negative affect scale measured via behavioural sampling using ecological momentary assessment (EMA) over four days. MSSD will be compared between baseline and post-treatment timepoints. | Before treatment, immediately after treatment + follow-up measure (3 months) | |
Secondary | Change in emotion regulation | Negative and neutral pictures are either presented with instruction to regulate or to respond naturally (view). BOLD response in the amygdala (and the rest of the brain) is measured and subjective ratings of regulation success are collected. Changes (between the time points) in differences of the two conditions (regulate vs. view) are measured for both: amygdala BOLD response and subjective ratings of regulation success. | Before treatment, immediately after treatment + follow-up measure (3 months) | |
Secondary | Change in borderline symptomatology | Facets of BPD are assessed with questionnaires, including impulsivity. Borderline Symptom List (BSL-23) score will be used for assesment of BPD symptoms. This scale has 23 items, each scored 0-4, and total score is mean item endorsement (sum of all items divided by 23). Higher scores indicate more symptom endorsement. | Before treatment, immediately after treatment + 2 follow-up measures (3 months, 6 months) | |
Secondary | Change in resting state brain connectivity | Patients get a 10 min brain scan (fMRI) without active task. Data are analysed to compare changes in intrinsic functional brain connectivity (BOLD activation of amygdala with other brain regions) during resting state before and after neurofeedback training. | Before treatment, immediately after treatment + follow-up measure (3 months) | |
Secondary | Change in amygdala reactivity | Patients will perform a task, in which blocks of faces with negative emotional expressions and scrambled pictures will be presented. This task leads to considerable amygdala activation. With this task, we want to observe effects of neurofeedback on spontaneous amygdala activation. | Before treatment, immediately after treatment + follow-up measure (3 months) | |
Secondary | Structural changes in the brain | By including DTI sequences before and after the neurofeedback intervention, we want to explore changes in FA/fiber structure of the brain. (exploratory analysis) | Before the first neurofeedback training and after the last neurofeedback training |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04856449 -
DBT Skills Plus EMDR for BPD and Trauma
|
N/A | |
Active, not recruiting |
NCT04587518 -
Five Factor Model Treatment for Borderline Personality Disorder
|
N/A | |
Recruiting |
NCT05651295 -
A Precision Medicine Approach to Target Engagement for Emotion Regulation
|
N/A | |
Completed |
NCT03677037 -
The Short-Term MBT Project
|
Phase 3 | |
Not yet recruiting |
NCT05989529 -
Delving Into Borderline Personality Disorder Clinical Trial Experiences
|
||
Completed |
NCT02518906 -
Evaluation of AIT Study
|
N/A | |
Completed |
NCT02068326 -
MBT in Groups for Adolescents With BPD or Subthreshold BPD Versus TAU - the M-GAB Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT04296604 -
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
|
N/A | |
Completed |
NCT02108990 -
Acetaminophen and Social Processes
|
Phase 2 | |
Terminated |
NCT02149823 -
Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations
|
Phase 1 | |
Completed |
NCT01635556 -
Evaluation of a Modified Dialectical Behavior Therapy Program
|
N/A | |
Not yet recruiting |
NCT01683136 -
Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Feasibility Study for the Treatment of Borderline Personality Disorder
|
N/A | |
Completed |
NCT02988037 -
Adapted Dialectical Behaviour Therapy for Adolescents With Deliberate Self-Harm: A Pre-post Observational Study
|
N/A | |
Completed |
NCT02397031 -
Mindfulness and Interpersonal Effectiveness Skills in Borderline Personality Disorder
|
N/A | |
Terminated |
NCT01103180 -
Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder
|
Phase 2 | |
Terminated |
NCT01212588 -
Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)
|
Phase 2 | |
Terminated |
NCT00539188 -
N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD
|
Phase 2 | |
Recruiting |
NCT05398627 -
Neurofeedback for Borderline Personality Disorder
|
N/A | |
Recruiting |
NCT03994510 -
SHame prOpensity in bOrderline Personality Disorder
|
N/A | |
Recruiting |
NCT06005129 -
Personality Change Study for Borderline Personality Disorder
|
N/A |